不推荐PSA低水平患者接受前列腺影像学检查

 
根据研究人员的说法，在接受明确的前列腺癌治疗之后，出现生化失败而没有症状的患者，在前列腺特异性抗原(PSA)小于5ng/ml的时候，影像学检查的价值很小。

这个结论是由美国Cleveland门诊部(Cleveland, OH, USA; www.clevelandclinic.org)的研究团队得出的，在2007年2月晚些时候在美国Kissimmee(FL, USA)举行的美国临床肿瘤学会(ASCO)前列腺研讨会上进行了报道，这些结论来自“前列腺战略泌尿系统研究计划(CaPSURE)”收集的数据，这是一项包括13,000例患者的数据库。CaPSURE数据库是美国观察注册处的男性活检标本确证疾病纵向数据。

Cleveland血液学和医学肿瘤学研究员Toni Choueiri医生指出：患者PSA水平低于5ng/ml其影像学检查出现阴性结果的可能性，要比那些生化失败而且PSA水平大于或者等于5ng/ml患者高出9倍。
 
Prostate Imaging Not Recommended for Men with Low PSA Levels
 
After definitive prostate cancer therapy, there is little value in imaging studies when patients with biochemical failure are asymptomatic and have prostate-specific assay (PSA) levels less than 5 ng/ml, according to researchers.

This conclusion, reported by a Cleveland Clinic (Cleveland, OH, USA; www.clevelandclinic.org) team of investigators at a prostate cancer symposium at American Society of Clinical Oncology (ASCO) held in Kissimmee (FL, USA) in late February 2007, emerged from data gathered from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a 13,000-patient database. The CaPSURE database is a U.S. observational registry with longitudinal data on men with biopsy-proven disease.

There was a ninefold increase in the likelihood of negative findings on imaging studies for patients with PSA levels below 5 ng/ml compared with patients whose biochemical failure was indicated by PSA levels 5 ng/ml or higher, said Toni Choueiri, M.D., a hematology and medical oncology fellow in Cleveland.